Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Novartis Institute of Biomedical Research relating to the ongoing access to a panel of X-MAN™ cell-lines.
X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first genetically-defined in-vitro models of human cancer and their matched normal cell-types, that help accelerate and rationalize the discovery of novel ‘personalised’ medicines and their optimal assessment in clinical trials.
The agreement covers the ongoing license of a panel of eight X-MAN cell lines that represent model genotypes of interest to Novartis.
“Chris Torrance, CEO of Horizon says “it is our aim to get our novel ‘patient-relevant’ X-MAN cancer models rapidly into the real world drug discovery arena and signing up Novartis is a big coup given their publically-stated interest in using predictive cell-models as a means of better defining patient populations ahead of expensive clinical trials”
Novartis will pay Horizon undisclosed up-front and renewal fees under the agreement which began in December 2008.